Gene expression profile of the human leukemia cell line Reh after treatment with bortezomib, valproic acid or a combination of both.. Homo sapiens

New therapy options are required for relapsed B-cell precursor ALL patients in order to improve survival and reduce adverse acute and late effects. We observed a synergistic anti-leukemic activity of concomitant treatment with bortezomib and valproic acid in BCP-ALL cells. In this experiment we aimed to identify the pathways modulated after concomitant treatment with bortezomib and valproic acid. Overall design: Reh cells treated with either bortezomib, valproic acid, or the combination of both normalized to a untreated control.